Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRM-151 in Idiopathic Pulmonary Fibrosis
CTR20211378Phase 3Terminated
- Sponsor
- Thermo Fisher Scientific
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of zinpentraxin alfa in idiopathic pulmonary fibrosis (IPF), sponsored by Thermo Fisher Scientific. Started Jun 2021; status: terminated.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20211378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211378.